comprehensive -WSS

comprehensive

author：fashion 2025-09-27 22:59:45 - browse：74631

An advisory committee to the Food and Drug Administration will convene on Tuesday to evaluate the benefits of renal denervation, a one-time surgical procedure that works to reduce blood pressure. The promise — and the potential market — is enormous, but the data on how well the procedure works remains contentious.

The committee will evaluate data from two companies vying for market approval: ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and device giant Medtronic, both of which have made surgical systems to treat hypertension.

Data from an analysis of three randomized clinical trials of ReCor Medical’s device showed a modest decrease in blood pressure after two months compared to a control group that received a placebo procedure. Medtronic’s late-stage trial showed that renal denervation reduced hypertension when measuring blood pressure in the doctor’s office, but did not show a reduction in blood pressure when patients measured it at home over 24 hours. At-home blood pressure is considered the more accurate measure, as blood pressure levels tend to artificially rise with anxiety in the clinic. Neither study presented serious safety concerns.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Will the market for weight loss drugs really reach $100 billion?

hotspot

leisure time

WSS

Churchill Downs extends trainer Bob Baffert's ban through 2024

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

3 killed, 8 injured in late

Mayo Clinic plans $5B tech

What don’t we know about an Alzheimer’s drug side effect?

UnitedHealth’s Optum accused of antitrust violations in California

hotspot

comprehensive

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

J&J to emphasize cancer drugs, stop much of its vaccine research

As demand for Covid shots wanes, Moderna seeks its next success

Michigan man accused of striking an officer during the US Capitol attack is arrested in Florida

Dobbs anniversary: the lost opportunity of abortion as health care

Ukraine holds disaster drills amid fears Russia could sabotage nuclear power plant

DIEP, the 'gold standard' of breast reconstruction, is under threat

Despite FDA concern, risk that CAR

FDA approval of Sarepta Duchenne genetic therapy gives me hope

10 states plan to sue EPA over standards for residential wood

knowledge

NASA releases new images of 'fingerprint

Mayo Clinic plans $5B tech

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Russians and Belarusians back at Wimbledon as war in Ukraine continues

Cigna, Humana reportedly in talks to merge

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

hotspot

leisure time

hotspot

Wikipedia